These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18086347)

  • 1. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
    Gandhi V; Balakrishnan K
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S8-12. PubMed ID: 18086347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.
    Furman RR; Hoelzer D
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S29-34. PubMed ID: 18086344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
    Korycka A; Błoński JZ; Robak T
    Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
    Gandhi V; Kilpatrick JM; Plunkett W; Ayres M; Harman L; Du M; Bantia S; Davisson J; Wierda WG; Faderl S; Kantarjian H; Thomas D
    Blood; 2005 Dec; 106(13):4253-60. PubMed ID: 16131572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.
    Balakrishnan K; Ravandi F; Bantia S; Franklin A; Gandhi V
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):458-66. PubMed ID: 23773454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
    Balakrishnan K; Nimmanapalli R; Ravandi F; Keating MJ; Gandhi V
    Blood; 2006 Oct; 108(7):2392-8. PubMed ID: 16778146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
    Galmarini CM
    IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.
    Ravandi F; Gandhi V
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1601-13. PubMed ID: 17107284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
    Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
    Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purine nucleoside phosphorylase inhibitors in T-cell malignancies.
    Bantia S; Kilpatrick JM
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):243-7. PubMed ID: 15603259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.
    Kicska GA; Long L; Hörig H; Fairchild C; Tyler PC; Furneaux RH; Schramm VL; Kaufman HL
    Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4593-8. PubMed ID: 11287638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forodesine: review of preclinical and clinical data.
    Al-Kali A; Gandhi V; Ayoubi M; Keating M; Ravandi F
    Future Oncol; 2010 Aug; 6(8):1211-7. PubMed ID: 20799866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents.
    Schramm VL
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):107-17. PubMed ID: 12084452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
    Bantia S; Ananth SL; Parker CD; Horn LL; Upshaw R
    Int Immunopharmacol; 2003 Jun; 3(6):879-87. PubMed ID: 12781704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
    Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
    Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of deoxyguanosine lymphotoxicity. Human thymocytes, but not peripheral blood lymphocytes accumulate deoxy-GTP in conditions simulating purine nucleoside phosphorylase deficiency.
    Fairbanks LD; Taddeo A; Duley JA; Simmonds HA
    J Immunol; 1990 Jan; 144(2):485-91. PubMed ID: 2104895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
    Larson RA
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S13-20. PubMed ID: 18086342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
    Bantia S; Miller PJ; Parker CD; Ananth SL; Horn LL; Kilpatrick JM; Morris PE; Hutchison TL; Montgomery JA; Sandhu JS
    Int Immunopharmacol; 2001 Jun; 1(6):1199-210. PubMed ID: 11407314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
    Balakrishnan K; Verma D; O'Brien S; Kilpatrick JM; Chen Y; Tyler BF; Bickel S; Bantia S; Keating MJ; Kantarjian H; Gandhi V; Ravandi F
    Blood; 2010 Aug; 116(6):886-92. PubMed ID: 20427701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biochemistry and pharmacology of PD 116124 (8-amino-2'-nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP).
    Dong MK; Scott ME; Schrier DJ; Suto MJ; Sircar JC; Black A; Chang T; Gilbertsen RB
    J Pharmacol Exp Ther; 1992 Jan; 260(1):319-26. PubMed ID: 1530976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.